Skip to main content
Reimbursement strategy

Cost-effective market access strategy for medical technologies in Europe

A holistic approach to reimbursement strategies trusted by global market leaders and SMEs

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

MTRC released a White Paper with a brief overview of the market access landscape for IVD tests in Europe

Market access for in-vitro diagnostic (IVD) testing is a challenging field. It includes co-existing frameworks of reimbursement (coding, payment mechanism tariffs), funding (post-reimbursement approval by payers), and health technology assessment (HTA). 

For most of the Med Tech companies, the starting point for understanding the European market is EU5 countries: England, France, Germany, Italy, and Spain.

Despite the single similarity of large populations, these countries are organized completely differently from the market access perspective.

MTRC developed an analytical White Paper with a summary of key market access elements of EU5 countries, including stakeholders, payment mechanisms, innovative payment schemes, funding, and the role of HTA for in-vitro diagnostic tests.

Read more and request a White Paper here.